Literature DB >> 8058798

Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.

B E Huber1, E A Austin, C A Richards, S T Davis, S S Good.   

Abstract

The gene encoding cytosine deaminase (CD) has been expressed in the human colorectal carcinoma cell line WiDr. Metabolism studies confirm that tumor cells expressing CD convert the very nontoxic prodrug 5-fluorocytosine (5FCyt) to 5-fluorouracil (5FUra) and 5FUra metabolites. Tumor xenografts composed of CD-expressing cells can selectively generate tumor levels of > 400 microM 5FUra when the host mouse is dosed with nontoxic levels of 5FCyt. The selective metabolic conversion of 5FCyt to 5FUra in CD-expressing tumor cells results in the inhibition of thymidylate synthase and incorporation of 5FUra into RNA. 5FUra is also liberated into the surrounding environment when CD-expressing tumor cells are treated with 5FCyt. The liberated 5FUra is able to kill neighboring, non-CD-expressing tumor cells in vitro and in vivo. Most importantly, when only 2% of the tumor mass contains CD-expressing cells (98% non-CD-expressing cells), significant regressions in all tumors are observed when the host mouse is dosed with nontoxic levels of 5FCyt.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8058798      PMCID: PMC44594          DOI: 10.1073/pnas.91.17.8302

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system.

Authors:  C A Mullen; M Kilstrup; R M Blaese
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

2.  Localization of the codA gene on the Escherichia coli chromosome.

Authors:  E A Austin; B E Huber
Journal:  J Bacteriol       Date:  1993-06       Impact factor: 3.490

3.  High affinity sodium-dependent nucleobase transport in cultured renal epithelial cells (LLC-PK1).

Authors:  D A Griffith; S M Jarvis
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

4.  In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase.

Authors:  B E Huber; E A Austin; S S Good; V C Knick; S Tibbels; C A Richards
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

5.  The transcriptional control region of the human carcinoembryonic antigen gene: DNA sequence and homology studies.

Authors:  C A Richards; A S Wolberg; B E Huber
Journal:  DNA Seq       Date:  1993

Review 6.  Prostate-specific antigen and diagnosing early malignancies of the prostate.

Authors:  J E Oesterling
Journal:  J Cell Biochem Suppl       Date:  1992

7.  A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase.

Authors:  E A Austin; B E Huber
Journal:  Mol Pharmacol       Date:  1993-03       Impact factor: 4.436

8.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

9.  The metabolism of 5-fluorocytosine-2-14-C and of cytosine-14-C in the rat and the disposition of 5-fluorocytosine-2-14-C in man.

Authors:  B A Koechlin; F Rubio; S Palmer; T Gabriel; R Duschinsky
Journal:  Biochem Pharmacol       Date:  1966-04       Impact factor: 5.858

Review 10.  Prostate-specific antigen: biochemistry, analytical methods, and clinical application.

Authors:  D A Armbruster
Journal:  Clin Chem       Date:  1993-02       Impact factor: 8.327

View more
  84 in total

Review 1.  Prodrug-activating systems in suicide gene therapy.

Authors:  C J Springer; I Niculescu-Duvaz
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Current status of gene therapy in gastroenterology.

Authors:  Chang-Tai Xu; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  1998-02       Impact factor: 5.742

Review 3.  Trials of gene therapy for pancreatic carcinoma.

Authors:  Christopher M Halloran; Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Curr Gastroenterol Rep       Date:  2005-06

4.  Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model.

Authors:  Florian Graepler; Marie-Luise Lemken; Wolfgang A Wybranietz; Ulrike Schmidt; Irina Smirnow; Christine D Gross; Martin Spiegel; Andrea Schenk; Hansjörg Graf; Ulrike A Lauer; Reinhard Vonthein; Michael Gregor; Sorin Armeanu; Michael Bitzer; Ulrich M Lauer
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

Review 5.  Human nerual stem cells for brain repair.

Authors:  Seung U Kim; Hong J Lee; In H Park; Kon Chu; Soon T Lee; Manho Kim; Jae K Roh; Seung K Kim; Kyu C Wang
Journal:  Int J Stem Cells       Date:  2008-11       Impact factor: 2.500

Review 6.  Novel treatment strategies for malignant gliomas using neural stem cells.

Authors:  Michael C Oh; Daniel A Lim
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

7.  Gene therapy in gastroenterology.

Authors:  H S Pandha; N R Lemoine
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

8.  Suicide gene approach using a dual-expression lentiviral vector to enhance the safety of ex vivo gene therapy for bone repair.

Authors:  F Alaee; O Sugiyama; M S Virk; H Tang; H Drissi; A C Lichtler; J R Lieberman
Journal:  Gene Ther       Date:  2013-11-28       Impact factor: 5.250

9.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.

Authors:  Lai Sum Leoh; Kouki Morizono; Kathleen M Kershaw; Irvin S Y Chen; Manuel L Penichet; Tracy R Daniels-Wells
Journal:  J Gene Med       Date:  2014 Jan-Feb       Impact factor: 4.565

10.  TK gene combined with mIL-2 and mGM-CSF genes in treatment of gastric cancer.

Authors:  Shan-Yu Guo; Qin-Long Gu; Zheng-Gang Zhu; He-Qun Hong; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.